Sai-Hong Ignatius Ou

Sai-Hong Ignatius Ou

Auto-generated profile, based on publicly available information

Sai-Hong Ignatius Ou

University of California Irvine School of Medicine, Orange, CA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in The Lancet Oncology
Verified
Journal Article
Closed access
SGShirish M Gadgeel
Shirish M Gadgeel
LGLeena Gandhi
Leena Gandhi
GRGregory J Riely
Gregory J Riely
ACAlberto A Chiappori
Alberto A Chiappori
HWHoward L West
Howard L West
SOSai-Hong Ignatius Ou
Sai-Hong Ignatius Ou

1 March 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SOSai-Hong Ignatius Ou
Sai-Hong Ignatius Ou
JAJin Seok Ahn
Jin Seok Ahn
LPLuigi De Petris
Luigi De Petris
RGRamaswamy Govindan
Ramaswamy Govindan
JYJames Chih-Hsin Yang
James Chih-Hsin Yang
DKDong-Wan Kim
Dong-Wan Kim
Purpose: Crizotinib confers improved progression-free survival compared with chemotherapy in anaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer (NSCLC), but progression invariably occurs. We investigated the efficacy and safety of alectinib, a potent and selective ALK inhibitor with excellent CNS penetration, in patients with crizotinib-refractory ALK-positive NSCLC. Patients and Methods: Alectinib 600 mg was administered orally twice daily. The primary end point was objective response rate (ORR) by central independent review committee (IRC). Results: Of the 138 patients treated, 84 patients (61%) had CNS metastases at baseline, and 122 were response evaluable (RE) by IRC. ORR by IRC was 50% (95% CI, 41% to 59%), and the median duration of response (DOR) was 11.2 months (95% CI, 9.6 months to not reached). In 96 patients (79%) previously treated with chemotherapy, the ORR was 45% (95% CI, 35% to 55%). Median IRC-assessed progression-free survival for all 138 patients was 8.9 months (95% CI, 5.6 to 11.3 months). CNS disease control rate was 83% (95% CI, 74% to 91%), and the median CNS DOR was 10.3 months (95% CI, 7.6 to 11.2 months). CNS ORR in 35 patients with baseline measurable CNS lesions was 57% (95% CI, 39% to 74%). Of the 23 patients with baseline CNS metastases (measurable or nonmeasurable) and no prior radiation, 10 (43%) had a complete CNS response. At 12 months, the cumulative CNS progression rate (24.8%) was lower than the cumulative non-CNS progression rate (33.2%) for all patients. Common adverse events were constipation (33%), fatigue (26%), and peripheral edema (25%); most were grade 1 to 2. Conclusion: Alectinib is highly active and well tolerated in patients with advanced, crizotinib-refractory ALK-positive NSCLC, including those with CNS metastases.

1 May 2011 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
PDF file
SOSai-Hong Ignatius Ou
Sai-Hong Ignatius Ou
EKEunice L. Kwak
Eunice L. Kwak
CSChristina Siwak-Tapp
Christina Siwak-Tapp
JDJoni Dy
Joni Dy
KBKristin Bergethon
Kristin Bergethon
AIA. John Iafrate
A. John Iafrate

1 September 2016 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
ASAlexa B. Schrock
Alexa B. Schrock
GFGarrett M. Frampton
Garrett M. Frampton
JSJames Suh
James Suh
ZCZachary R. Chalmers
Zachary R. Chalmers
MRMark Rosenzweig
Mark Rosenzweig
SOSai-Hong Ignatius Ou
Sai-Hong Ignatius Ou
The hepatocyte growth factor receptor gene (MET) exon 14 skipping (METex14) has recently been described a potential driver alteration in lung cancer targetable by mesenchymal-to-epithelial transition factor (MET) tyrosine kinase inhibitors (TKIs). Well-validated hybrid capture-based comprehensive genomic profiling was performed at the request of individual treating physicians. Of 11,205 lung cancers profiled by comprehensive genomic profiling, 298 (2.7%) carcinomas harbored alterations predicted to cause METex14, including adenosquamous (8.2%), sarcomatoid (7.7%), histologic subtype not otherwise specified (3.0%), adenocarcinoma (2.9%), squamous cell (2.1%), large cell (0.8%), and SCLC (0.2%). Acinar features were present in 24% of the METex14 samples. Six cases (2%) harbored MET Y1003X mutations affecting binding of the MET-negative regulator, E3 ubiquitin protein ligase. The median age of all patients with METex14 was 73 years (range 43-95) and 60% were female. Concurrent, murine double minute gene (MDM2) amplification, cyclin-dependent kinase 4 gene (CDK4) amplification, and EGFR amplification were observed in 35%, 21%, and 6.4% of patients with METex14, respectively. KRAS mutation was observed in 3% of cases. Concurrent MET amplification (METamp) (median copy number 10) was identified in 15% of METex14 samples. Significant differences in tumor mutational burden and type of the METex14 alterations were observed between the METamp and non-METamp samples. Response to MET TKI was observed in both in patients with METamp and in patients without METamp METex14. Diverse targetable METex14 alterations were identified in patients with NSCLC across age groups, including elderly patients, and in all major NSCLC histologic subtypes with an overall frequency of 2.7%. These findings support the use of hybrid capture-based molecular profiling across NSCLC subtypes to identify patients who will potentially benefit from MET TKIs.

15 February 2022 in Journal of Clinical Oncology
Verified
Journal Article
Open access
SOSai-Hong Ignatius Ou
Sai-Hong Ignatius Ou
PJPasi Antero Jänne
Pasi Antero Jänne
TLTiciana A. Leal
Ticiana A. Leal
IRIgor I. Rybkin
Igor I. Rybkin
JSJoshua K. Sabari
Joshua K. Sabari
KPKyriakos P. Papadopoulos
Kyriakos P. Papadopoulos
PURPOSE: Adagrasib (MRTX849) is an oral, highly selective, small-molecule, covalent inhibitor of KRASG12C. We report results from a phase I/IB study of adagrasib in non–small-cell lung cancer, colorectal cancer, and other solid tumors harboring the KRAS G12C mutation. MATERIALS AND METHODS: Patients with advanced KRAS G12C-mutant solid tumors were treated with adagrasib 150 mg orally once daily, 300 mg once daily, 600 mg once daily, 1,200 mg once daily, or 600 mg orally twice a day using an accelerated titration design, which transitioned to a modified toxicity probability interval design when a predefined degree of toxicity was observed or target adagrasib exposure was achieved. Safety, pharmacokinetics, and clinical activity were evaluated. RESULTS: Twenty-five patients were enrolled and received at least one dose of adagrasib. The recommended phase II dose (RP2D) was 600 mg twice a day on the basis of safety, tolerability, and observed pharmacokinetics properties. No maximum tolerated dose was formally defined. After a median follow-up of 19.6 months, eight of 15 patients (53.3%; 95% CI, 26.6 to 78.7) with RECIST-evaluable KRAS G12C-mutant non–small-cell lung cancer treated at 600 mg twice a day achieved a confirmed partial response. The median duration of response was 16.4 months (95% CI, 3.1 to not estimable). The median progression-free survival was 11.1 months (95% CI, 2.6 to not estimable). One of two patients with KRAS G12C-mutant colorectal cancer treated at 600 mg twice a day achieved a partial response (duration of response, 4.2 months). At the RP2D, the most common treatment-related adverse events (any grade) were nausea (80.0%), diarrhea (70.0%), vomiting (50.0%), and fatigue (45.0%). The most common grade 3-4 treatment-related adverse event was fatigue (15.0%). CONCLUSION: Adagrasib 600 mg twice a day was well tolerated and exhibited antitumor activity in patients with advanced solid tumors harboring the KRAS G12C mutation.

14 August 2007 in Cancer
Verified
Journal Article
Open access
PDF file
SOS.‐H. Ignatius Ou
S.‐H. Ignatius Ou
JZJason A. Zell
Jason A. Zell
AZArgyrios Ziogas
Argyrios Ziogas
HAHoda Anton‐Culver
Hoda Anton‐Culver
BACKGROUND.: Platinum‐based adjuvant chemotherapy in randomized trials has failed to provide a survival benefit in patients with resected stage I nonsmall cell lung cancer (NSCLC). Using data from the California Cancer Registry (CCR), we explored factors that had detrimental effects on survival in patients with stage I NSCLC to identify a subset of patients at high risk for disease recurrence and subsequent mortality.METHODS.: Between 1989 and 2003, 19,702 incident cases of stage I NSCLC in the CCR were identified and subgrouped into stage IA and IB disease. Patient demographic factors, tumor characteristics, and treatment delivered were examined. Kaplan‐Meier survival curves were calculated to estimate survival rates. Cox proportional‐hazards ratios were used to identify independent prognostic factors for survival.RESULTS.: Advanced age at diagnosis, male sex, low socioeconomic status (SES), nonsurgical treatment, and poor histologic grade (stage IA NSCLC: hazards ratio [HR], 1.13; 95% confidence interval [95% CI], 1.08–1.19; stage IB NSCLC: HR, 1.11; 95% CI, 1.07–1.16) were associated with increased mortality risk on multivariate analysis. Nonupper lobe tumor location (right middle lobe, right and left lower lobes) and tumor size ≥4 cm (vs <4 cm: HR, 1.23; 95% CI, 1.15–1.30) were additional factors that increased the risk of mortality among patients with stage IB disease. Bronchioloalveolar carcinoma and Asian ethnicity were associated with decreased mortality risk in stage I NSCLC.CONCLUSIONS.: Stage I NSCLC with poorly differentiated histology and stage IB NSCLC with nonupper lobar tumor location or tumor size ≥4 cm carried an increased mortality risk. Cancer 2007. © 2007 American Cancer Society.